A
Akebia Ther (AKBA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
$0.45
-0.03 (-5.40%)
Market Cap: $131.67M
Last updated: Nov 17, 2026 at 11:04 AM ET
Akebia Ther (AKBA) Valuation Multiples
Akebia Ther (AKBA) trades at 0.6x sales and 6.1x book value. Its P/S of 0.6x is below its 5-year median of 1.6x. Its forward P/E is 24.6x.
Current Multiples
Its free cash flow yield is 11.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 24.6x |
| Price to sales | 0.6x |
| Price to book | 6.1x |
| Price to FCF | 9.0x |
| EV/FCF | 1.1x |
| PEG | N/A |
| FCF yield | 11.2% |
Historical Medians
Against its 10-year medians, its P/S is 66.7% below 1.8x and its P/B is 69.4% above 3.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 0.6x | 1.6x | 1.8x |
| P/B | 6.1x | N/A | 3.6x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.2x in 2023 to 262.9x in 2016.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $1.61 | 1.7x | 13.1x |
| 2024 | $1.90 | 2.5x | N/A |
| 2023 | $1.24 | 1.2x | N/A |
| 2022 | $0.58 | N/A | 20.3x |
| 2021 | $2.26 | 1.8x | 5.4x |
| 2020 | $2.80 | 1.3x | 1.6x |
| 2019 | $6.32 | 2.2x | 1.9x |
| 2018 | $5.53 | 1.7x | 1.0x |
| 2017 | $14.87 | 3.7x | 6.1x |
| 2016 | $10.41 | 262.9x | 5.9x |
Frequently Asked Questions About AKBA
What is AKBA's forward P/E ratio?
Akebia Ther has a forward P/E ratio of 24.6x.
What is AKBA's price to sales ratio?
Akebia Ther has a price to sales ratio of 0.6x.
AKBA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors